• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

    4/2/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care
    Get the next $NARI alert in real time by email

    IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari's mission to improve patient care through physician education and new device development.

    "We are thrilled to welcome Tim to Inari. His extensive experience leading the commercial execution of disruptive healthcare technologies will serve him well as he spearheads our U.S. commercial efforts," said Drew Hykes, CEO of Inari.

    Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies. Most recently, Tim spearheaded the global launch and commercial execution of Saluda Medical's disruptive closed-loop neuromodulation platform. Before joining Saluda, Tim was Global GM and SVP of Terumo's Blood and Cell Technologies business and led the global commercial business at Endologix. Prior to his time at Terumo and Endologix, Tim was responsible for commercial leadership of the U.S. Structural Heart business at Abbott and oversaw the execution of hyper-growth therapies such as MitraClip, Amulet, and Portico. Tim joined Abbott after approximately 10 years at Edwards Lifesciences where he oversaw several functions across Global Marketing, Commercial Operations, Global Strategy, and Business Development. Tim began his career at Honda where he worked in R&D and Advanced Development.

    "Dr. Niekamp is a gifted clinician and a passionate and clear communicator. We are honored to add his talents to our Medical Affairs team," said Dr. Thomas Tu, Chief Medical Officer of Inari.

    Prior to joining Inari, Dr. Niekamp was a Vascular Interventional Radiologist with Radiology Associates of South Florida and joined the group in July of 2020. He also practiced at Baptist Hospital of Miami, South Miami Hospital and Doctors Hospital. Dr. Niekamp received his undergraduate degree and medical degree from The Ohio State University and completed his post-graduate training at the University of Texas at Houston/M.D. Anderson Cancer Center. He completed his fellowship in Vascular Interventional Radiology at the Miami Cardiac and Vascular Institute. Following fellowship, he joined the faculty at Miami Cardiac and Vascular Institute and was a practicing attending until March 2024. Dr. Niekamp has been an investigator in multiple clinical research trials and is the author of numerous papers and abstracts. During his time in practice, Dr. Niekamp had a particular focus on treating patients suffering from venous thromboembolism.

    About Inari Medical, Inc.

    Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease, and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.

    Investor Contact:

    John Hsu, CFA

    VP, Investor Relations

    949-658-3889

    [email protected]



    Primary Logo

    Get the next $NARI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NARI

    DatePrice TargetRatingAnalyst
    12/17/2024$75.00Outperform
    Oppenheimer
    9/18/2024$50.00Hold
    Stifel
    9/3/2024$47.00Market Perform
    Leerink Partners
    8/9/2024$68.00Buy
    Deutsche Bank
    7/25/2024Outperform
    William Blair
    7/18/2024Buy → Hold
    Needham
    2/29/2024$85.00 → $55.00Overweight → Neutral
    Piper Sandler
    1/23/2024$72.00Buy
    Needham
    More analyst ratings

    $NARI
    SEC Filings

    View All

    SEC Form 15-12G filed by Inari Medical Inc.

    15-12G - Inari Medical, Inc. (0001531048) (Filer)

    3/3/25 6:06:19 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by Inari Medical Inc.

    25-NSE - Inari Medical, Inc. (0001531048) (Subject)

    2/19/25 9:11:12 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Inari Medical Inc.

    S-8 POS - Inari Medical, Inc. (0001531048) (Filer)

    2/19/25 9:07:02 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Inari with a new price target

    Oppenheimer initiated coverage of Inari with a rating of Outperform and set a new price target of $75.00

    12/17/24 7:53:14 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Inari with a new price target

    Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00

    9/18/24 7:45:45 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Leerink Partners initiated coverage on Inari with a new price target

    Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00

    9/3/24 8:10:13 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

    Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

    2/19/25 8:30:00 AM ET
    $NARI
    $SYK
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    $NARI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4) (Amendment)

    4/A - Inari Medical, Inc. (0001531048) (Issuer)

    5/31/24 4:54:38 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    11/8/23 5:48:54 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Warner Robert Keith closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:26:35 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:22:46 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Director Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)

    4 - Inari Medical, Inc. (0001531048) (Issuer)

    2/19/25 8:20:54 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Financials

    Live finance-specific insights

    View All

    Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

    Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

    2/19/25 8:30:00 AM ET
    $NARI
    $SYK
    Medical/Dental Instruments
    Health Care

    Inari Medical Reports Third Quarter 2024 Financial Results

    IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t

    10/28/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Inari Medical to Announce Third Quarter 2024 Financial Results

    IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc

    10/7/24 4:05:00 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    $NARI
    Leadership Updates

    Live Leadership Updates

    View All

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $NARI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/8/24 2:17:22 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/8/24 10:29:30 AM ET
    $NARI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

    11/7/24 4:49:55 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care